Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Snusbolaget in connection with the acquisition of Northerner
Mandate

Vinge has advised Snusbolaget in connection with the acquisition of Northerner

October 01, 2019 M&A

Vinge has advised Snusbolaget Norden Holding AB in connection with the acquisition of Northerner Scandinavia AB

The E‑trading company Snusbolaget sells snus and tobacco‑free nicotine pouches from other suppliers online. In 2018, the company had a turnover of SEK 500 million and grew by 65 per cent. In 2018, Northerner had a turnover of approximately SEK 100 million. Following the acquisition, the company will be called Haypp Group and will have approximately 500,000 customers in 80 countries in Europe, Asia and the United States with an anticipated turnover in 2019 of almost SEK 1 billion.


Vinge’s team consisted of partner Kristian Ford together with, among others, associates Niklas Törnell, Sophia Reutercrona, Tilda Hall, Fredrik Christiansson, Jack Bengtsson and Emelie Svensäter Jerntorp.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024